Nature's Sunshine Products (NATR) 10-Q 4 Nov 21 2021 Q3 Quarterly report Financial data

Cover Page

Cover Page - shares	9 Months Ended
	Sep. 30, 2021	Oct. 22, 2021
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2021
Document Transition Report	false
Entity File Number	001-34483
Entity Registrant Name	NATURE’S SUNSHINE PRODUCTS, INC.
Entity Incorporation, State or Country Code	UT
Entity Tax Identification Number	87-0327982
Entity Address, Address Line One	2901 Bluegrass Boulevard
Entity Address, Address Line Two	Suite 100
Entity Address, City or Town	Lehi
Entity Address, State or Province	UT
Entity Address, Postal Zip Code	84043
City Area Code	801
Local Phone Number	341-7900
Title of 12(b) Security	Common Stock, no par value
Trading Symbol	NATR
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		19,760,612
Entity Central Index Key	0000275053
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q3
Security Exchange Name	NASDAQ

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 75,535	$ 92,069
Accounts receivable, net of allowance for doubtful accounts of $445 and $454, respectively	9,189	7,375
Inventories	57,376	47,683
Prepaid expenses and other	8,627	6,938
Total current assets	150,727	154,065
Property, plant and equipment, net	52,538	54,355
Operating lease right-of-use assets	19,136	20,210
Investment securities - trading	950	989
Deferred income tax assets	5,842	8,693
Other assets	10,559	11,186
Total assets	239,752	249,498
Current liabilities:
Accounts payable	7,580	6,486
Accrued volume incentives and service fees	21,868	19,481
Accrued liabilities	29,606	31,710
Deferred revenue	1,513	2,092
Related party notes payable	600	1,200
Income taxes payable	3,540	2,387
Current portion of operating lease liabilities	4,495	4,992
Current portion of note payable	1,235	1,306
Total current liabilities	70,437	69,654
Liability related to unrecognized tax benefits	5	92
Long-term portion of operating lease liabilities	16,510	16,412
Long-term note payable	1,488	2,418
Deferred compensation payable	950	989
Deferred income tax liabilities	1,574	1,391
Other liabilities	1,158	1,308
Total liabilities	92,122	92,264
Shareholders’ equity:
Common stock, no par value, 50,000 shares authorized, 19,775 and 19,697 shares issued and outstanding, respectively	134,252	139,311
Retained earnings	21,586	26,030
Noncontrolling interest	2,838	1,848
Accumulated other comprehensive loss	(11,046)	(9,955)
Total shareholders’ equity	147,630	157,234
Total liabilities and shareholders’ equity	$ 239,752	$ 249,498

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Accounts receivable, allowance for doubtful accounts	$ 445	$ 454
Common stock, no par value (in dollars per share)	$ 0	$ 0
Common stock, shares outstanding (in shares)	19,775,000	19,697,000
Common stock, shares authorized (in shares)	50,000,000	50,000,000
Common stock, shares issued (in shares)	19,775,000	19,697,000

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Income Statement [Abstract]
Net sales	$ 114,746	$ 100,250	$ 326,145	$ 283,462
Cost of sales	29,419	27,175	84,861	74,873
Gross profit	85,327	73,075	241,284	208,589
Operating expenses:
Volume incentives	35,793	34,310	105,491	96,493
Selling, general and administrative	39,528	33,294	108,666	92,863
Operating income	10,006	5,471	27,127	19,233
Other income (loss), net	(886)	671	(2,290)	(230)
Income before provision for income taxes	9,120	6,142	24,837	19,003
Provision (benefit) for income taxes	3,662	(1,027)	8,433	2,695
Net income	5,458	7,169	16,404	16,308
Net income attributable to noncontrolling interests	600	414	990	837
Net income attributable to common shareholders	$ 4,858	$ 6,755	$ 15,414	$ 15,471
Earnings Per Share [Abstract]
Basic earnings per share attributable to common shareholders (in dollars per share)	$ 0.24	$ 0.35	$ 0.77	$ 0.79
Diluted earnings per share attributable to common shareholders (in dollars per share)	$ 0.24	$ 0.34	$ 0.76	$ 0.78
Weighted average basic common shares outstanding (in shares)	19,894	19,533	19,896	19,493
Weighted average diluted common shares outstanding (in shares)	20,375	19,859	20,292	19,820
Dividends declared per common share (in dollars per share)			$ 1	$ 0

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Statement of Comprehensive Income [Abstract]
Net income	$ 5,458	$ 7,169	$ 16,404	$ 16,308
Foreign currency translation income (loss) (net of tax)	(925)	718	(1,091)	458
Total comprehensive income	$ 4,533	$ 7,887	$ 15,313	$ 16,766

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Common Stock	Retained Earnings	Noncontrolling Interest	Accumulated Other Comprehensive Loss
Beginning balance (in shares) at Dec. 31, 2019		19,410,000
Beginning balance at Dec. 31, 2019	$ 129,436	$ 135,741	$ 4,693	$ 227	$ (11,225)
Increase (Decrease) in Shareholders' Equity
Share-based compensation expense	394	$ 394
Shares issued from the exercise of stock options and vesting of restricted stock units, net of shares exchanged for withholding tax (in shares)		60,000
Shares issued from the exercise of stock options and vesting of restricted stock units, net of shares exchanged for withholding tax	(159)	$ (159)
Net income	3,006		2,962	44
Other comprehensive loss	(109)				(109)
Ending balance (in shares) at Mar. 31, 2020		19,470,000
Ending balance at Mar. 31, 2020	132,568	$ 135,976	7,655	271	(11,334)
Beginning balance (in shares) at Dec. 31, 2019		19,410,000
Beginning balance at Dec. 31, 2019	129,436	$ 135,741	4,693	227	(11,225)
Increase (Decrease) in Shareholders' Equity
Net income	16,308
Ending balance (in shares) at Sep. 30, 2020		19,592,000
Ending balance at Sep. 30, 2020	148,237	$ 137,776	20,164	1,064	(10,767)
Beginning balance (in shares) at Mar. 31, 2020		19,470,000
Beginning balance at Mar. 31, 2020	132,568	$ 135,976	7,655	271	(11,334)
Increase (Decrease) in Shareholders' Equity
Share-based compensation expense	736	$ 736
Shares issued from the exercise of stock options and vesting of restricted stock units, net of shares exchanged for withholding tax (in shares)		40,000
Shares issued from the exercise of stock options and vesting of restricted stock units, net of shares exchanged for withholding tax	(51)	$ (51)
Net income	6,133		5,754	379
Other comprehensive loss	(151)				(151)
Ending balance (in shares) at Jun. 30, 2020		19,510,000
Ending balance at Jun. 30, 2020	139,235	$ 136,661	13,409	650	(11,485)
Increase (Decrease) in Shareholders' Equity
Share-based compensation expense	1,011	$ 1,011
Shares issued from the exercise of stock options and vesting of restricted stock units, net of shares exchanged for withholding tax (in shares)		82,000
Shares issued from the exercise of stock options and vesting of restricted stock units, net of shares exchanged for withholding tax	104	$ 104
Net income	7,169		6,755	414
Other comprehensive loss	718				718
Ending balance (in shares) at Sep. 30, 2020		19,592,000
Ending balance at Sep. 30, 2020	$ 148,237	$ 137,776	20,164	1,064	(10,767)
Beginning balance (in shares) at Dec. 31, 2020	19,697,000	19,697,000
Beginning balance at Dec. 31, 2020	$ 157,234	$ 139,311	26,030	1,848	(9,955)
Increase (Decrease) in Shareholders' Equity
Share-based compensation expense	1,005	$ 1,005
Shares issued from the exercise of stock options and vesting of restricted stock units, net of shares exchanged for withholding tax (in shares)		218,000
Shares issued from the exercise of stock options and vesting of restricted stock units, net of shares exchanged for withholding tax	(914)	$ (914)
Cash dividends	(19,858)		(19,858)
Net income	4,152		4,016	136
Other comprehensive loss	(121)				(121)
Ending balance (in shares) at Mar. 31, 2021		19,915,000
Ending balance at Mar. 31, 2021	$ 141,498	$ 139,402	10,188	1,984	(10,076)
Beginning balance (in shares) at Dec. 31, 2020	19,697,000	19,697,000
Beginning balance at Dec. 31, 2020	$ 157,234	$ 139,311	26,030	1,848	(9,955)
Increase (Decrease) in Shareholders' Equity
Net income	$ 16,404
Ending balance (in shares) at Sep. 30, 2021	19,775,000	19,775,000
Ending balance at Sep. 30, 2021	$ 147,630	$ 134,252	21,586	2,838	(11,046)
Beginning balance (in shares) at Mar. 31, 2021		19,915,000
Beginning balance at Mar. 31, 2021	141,498	$ 139,402	10,188	1,984	(10,076)
Increase (Decrease) in Shareholders' Equity
Share-based compensation expense	1,066	$ 1,066
Shares issued from the exercise of stock options and vesting of restricted stock units, net of shares exchanged for withholding tax (in shares)		152,000
Shares issued from the exercise of stock options and vesting of restricted stock units, net of shares exchanged for withholding tax	(660)	$ (660)
Repurchase of common stock (in shares)		(77,000)
Repurchase of common stock	(1,500)	$ (1,500)
Net income	6,794		6,540	254
Other comprehensive loss	(45)				(45)
Ending balance (in shares) at Jun. 30, 2021		19,990,000
Ending balance at Jun. 30, 2021	147,153	$ 138,308	16,728	2,238	(10,121)
Increase (Decrease) in Shareholders' Equity
Share-based compensation expense	886	$ 886
Shares issued from the exercise of stock options and vesting of restricted stock units, net of shares exchanged for withholding tax (in shares)		58,000
Shares issued from the exercise of stock options and vesting of restricted stock units, net of shares exchanged for withholding tax	(442)	$ (442)
Repurchase of common stock (in shares)		(273,000)
Repurchase of common stock	(4,500)	$ (4,500)
Net income	5,458		4,858	600
Other comprehensive loss	$ (925)				(925)
Ending balance (in shares) at Sep. 30, 2021	19,775,000	19,775,000
Ending balance at Sep. 30, 2021	$ 147,630	$ 134,252	$ 21,586	$ 2,838	$ (11,046)

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$ 16,404	$ 16,308
Adjustments to reconcile net income to net cash provided by operating activities:
Provision for doubtful accounts	0	116
Depreciation and amortization	8,276	7,834
Non-cash lease expense	4,043	2,398
Share-based compensation expense	2,957	2,141
Loss on sale of property, plant and equipment	24	7
Deferred income taxes	2,891	1,210
Purchase of trading investment securities	(30)	(47)
Proceeds from sale of trading investment securities	175	221
Realized and unrealized gains on investments	(62)	(41)
Foreign exchange losses	2,483	354
Changes in assets and liabilities:
Accounts receivable	(2,054)	(1,692)
Inventories	(10,771)	(1,361)
Prepaid expenses and other current assets	(1,787)	(798)
Other assets	(267)	(30)
Accounts payable	421	1,102
Accrued volume incentives and service fees	2,750	(1,370)
Accrued liabilities	(1,646)	5,106
Deferred revenue	(551)	295
Lease liabilities	(4,170)	(2,276)
Income taxes payable	1,316	(1,078)
Liability related to unrecognized tax benefits	(87)	(1,417)
Deferred compensation payable	(34)	(133)
Net cash provided by operating activities	20,281	26,849
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property, plant and equipment	(4,626)	(3,487)
Net cash used in investing activities	(4,626)	(3,487)
CASH FLOWS FROM FINANCING ACTIVITIES:
Payments of cash dividends	(19,858)	0
Principal payments of long-term debt	(1,001)	0
Proceeds from note payable	0	5,374
Principal payments of related party borrowing	(600)	(243)
Proceeds from the exercise of stock awards	0	192
Payments related to tax withholding for net-share settled equity awards	(2,016)	0
Tax benefit from exercise of stock options		(298)
Repurchase of common stock	(6,000)	0
Net cash provided by (used in) financing activities	(29,475)	5,025
Effect of exchange rates on cash and cash equivalents	(2,714)	244
Net increase (decrease) in cash and cash equivalents	(16,534)	28,631
Cash and cash equivalents at the beginning of the period	92,069	53,629
Cash and cash equivalents at the end of the period	75,535	82,260
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid for income taxes, net of refunds	4,431	3,293
Cash paid for interest	$ 156	$ 24

CONDENSED CONSOLIDATED STATEM_5

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (PARENTHETICAL) - $ / shares	3 Months Ended	9 Months Ended
	Mar. 31, 2021	Sep. 30, 2021	Sep. 30, 2020
Statement of Stockholders' Equity [Abstract]
Cash dividend (in dollars per share)	$ 1	$ 1	$ 0

Basis of Presentation

Basis of Presentation	9 Months Ended
	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation We are a natural health and wellness company primarily engaged in the manufacture and sale of nutritional and personal care products. We are a Utah corporation with our principal place of business in Lehi, Utah, and sell our products to a sales force of independent consultants who use the products themselves or resell them to consumers. Principles of Consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. The unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany accounts and transactions are eliminated in consolidation. In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting of normal recurring accruals), considered necessary for a fair presentation of our financial information as of September 30, 2021, and for the three and nine-month periods ended September 30, 2021 and 2020. The results of operations of any interim period are not necessarily indicative of the results of operations to be expected for the year ending December 31, 2021. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2020 as amended by Form 10-K/A on July 9, 2021. Use of Estimates The preparation of consolidated financial statements in accordance with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities, in these financial statements and accompanying notes. Actual results could differ from these estimates due to the uncertainty around the magnitude and duration of the COVID-19 pandemic, as well as other factors and those differences could have a material effect on our financial position and results of operations. The significant accounting estimates inherent in the preparation of our financial statements include estimates associated with our determination of liabilities related to independent consultant incentives, the determination of income tax assets and liabilities, certain other non-income tax and value-added tax contingencies, and legal contingencies. In addition, significant estimates form the basis for allowances with respect to inventory valuations. Various assumptions and other factors enter into the determination of these significant estimates. The process of determining significant estimates takes into account historical experience and current and expected economic conditions. Noncontrolling Interests Noncontrolling interests changed as a result of the net income attributable to noncontrolling interests of $0.6 million and $1.0 million for the three and nine months ended September 30, 2021, respectively. Net income attributable to the noncontrolling interests was $0.4 million and $0.8 million for the three and nine months ended September 30, 2020, respectively. As of September 30, 2021 and December 31, 2020, noncontrolling interests were $2.8 million and $1.8 million, respectively. Restructuring Related Accruals and Expenses We recorded $0 and $48,000 of restructuring related expenses during the three and nine months ended September 30, 2021, respectively. We recorded $0 and $0.1 million of restructuring related expenses during the three and nine months ended September 30, 2020, respectively. Accrued severance and restructuring related costs were $0 and $0.4 million as of September 30, 2021 and December 31, 2020, respectively. Recent Accounting Pronouncements In December 2019, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. This ASU eliminates certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating taxes during the quarters and the recognition of deferred tax liabilities for outside basis differences. The amendments in this update are effective for reporting periods beginning after December 15, 2020. The adoption of this ASU did not have a significant impact on our Consolidated Financial Statements. In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting. This ASU provides optional guidance for a limited period of time to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting. The amendments in this update are elective and subject to meeting certain criteria, that have contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. This could affect balances of right of use assets, lease liabilities, and notes payables. The amendments in this update are effective as of March 12, 2020 through December 21, 2022. The adoption of this ASU is not expected to have a significant impact on our Consolidated Financial Statements.

Inventories

Inventories	9 Months Ended
	Sep. 30, 2021
Inventory Disclosure [Abstract]
Inventories	Inventories The composition of inventories is as follows (dollar amounts in thousands): September 30, December 31, Raw materials $ 19,603 $ 13,956 Work in progress 1,619 1,351 Finished goods 36,154 32,376 Total inventories $ 57,376 $ 47,683

Investment Securities - Trading

Investment Securities - Trading	9 Months Ended
	Sep. 30, 2021
Investments, Debt and Equity Securities [Abstract]
Investment Securities - Trading	Investment Securities - Trading Our trading securities portfolio totaled $1.0 million at September 30, 2021, and $1.0 million at December 31, 2020, and generated losses of $4,000 and gains of $45,000 for the three months ended September 30, 2021 and 2020, respectively, and gains of $62,000 and gains of $41,000 for the nine months ended September 30, 2021 and 2020, respectively.

Revolving Credit Facility and O

Revolving Credit Facility and Other Obligations	9 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
Revolving Credit Facility and Other Obligations	Revolving Credit Facility and Other Obligations On July 11, 2017, we entered into a revolving credit agreement with Bank of America, N.A., with a borrowing limit of $25.0 million (the “Credit Agreement”). On June 11, 2020 the credit agreement was amended to extend the term to mature on July 1, 2023. The amendment also allows for additional borrowings of $15.0 million or up to three separate increases of no less than $5.0 million each. On March 8, 2021, we signed an amendment to the credit agreement that eliminates the Index floor from the calculation of interest. We pay interest on any borrowings under the Credit Agreement, which through March 8, 2021, was at LIBOR, or the Index floor of 0.75 percent, plus 2.25 percent (3.00 percent as of December 31, 2020), and an annual commitment fee of 0.25 percent on the unused portion of the commitment. Interest under the amended Credit Agreement is at LIBOR, plus 2.25 percent (2.33 percent as of September 30, 2021), and an annual commitment fee of 0.25 percent on the unused portion of the commitment. We are required to settle our net borrowings under the Credit Agreement only upon maturity, and as a result, have classified prior outstanding borrowings as non-current on our condensed consolidated balance sheet. At September 30, 2021, there was no outstanding balance under the Credit Agreement. The Credit Agreement contains customary financial covenants, including financial covenants relating to our solvency and leverage. In addition, the Credit Agreement restricts certain capital expenditures, lease expenditures, other indebtedness, liens on assets, guarantees, loans and advances, dividends, mergers, consolidations and transfers of assets except as permitted in the Credit Agreement. The Credit Agreement is collateralized by our manufacturing facility, accounts receivable, inventories and other assets. As of September 30, 2021, we were in compliance with the debt covenants set forth in the Credit Agreement. On April 21, 2020, we entered into a credit agreement with Banc of America Leasing and Capital, LLC, with a borrowing limit of $6.0 million (the "Capital Credit Agreement"). On November 19, 2020, we executed on the Capital Credit Agreement and borrowed $3.7 million. We currently do not expect to make any additional borrowings under the Capital Credit Agreement. We pay interest on any borrowings under the Capital Credit Agreement at a fixed rate of 3.00 percent and are

Net Income Per Share

Net Income Per Share	9 Months Ended
	Sep. 30, 2021
Earnings Per Share [Abstract]
Net Income Per Share	Net Income Per Share Basic net income per common share (“Basic EPS”), is computed by dividing net income by the weighted average number of common shares outstanding during the period. Diluted net income per common share (“Diluted EPS”) reflects the potential dilution that could occur if stock options or other contracts to issue common stock were exercised or converted into common stock. The computation of Diluted EPS does not assume exercise or conversion of securities that would have an anti-dilutive effect on net income per common share. Following is a reconciliation of the numerator and denominator of Basic EPS to the numerator and denominator of Diluted EPS for the three and nine months ended September 30, 2021 and 2020 (dollar and share amounts in thousands, except for per share information): Three Months Ended Nine Months Ended 2021 2020 2021 2020 Net income attributable to common shareholders $ 4,858 $ 6,755 $ 15,414 $ 15,471 Basic weighted average shares outstanding 19,894 19,533 19,896 19,493 Basic earnings per share attributable to common shareholders $ 0.24 $ 0.35 $ 0.77 $ 0.79 Diluted shares outstanding: Basic weighted-average shares outstanding 19,894 19,533 19,896 19,493 Stock-based awards 481 326 396 327 Diluted weighted-average shares outstanding 20,375 19,859 20,292 19,820 Diluted earnings per share attributable to common shareholders $ 0.24 $ 0.34 $ 0.76 $ 0.78 Dilutive shares excluded from diluted-per-share amounts: Stock options 460 791 460 791 Anti-dilutive shares excluded from diluted-per-share amounts: Stock options — 199 — 199 Potentially dilutive shares excluded from diluted-per-share amounts include performance-based options to purchase shares of common stock for which certain earnings metrics have not been achieved. Potentially anti-dilutive shares excluded from diluted-per-share amounts include both non-qualified stock options and unearned performance-based options to purchase shares of common stock with exercise prices greater than the weighted- average share price during the period and shares that would be anti-dilutive to the computation of diluted net income per share for each of the periods presented.

Capital Transactions

Capital Transactions	9 Months Ended
	Sep. 30, 2021
Equity [Abstract]
Capital Transactions	Capital Transactions Dividends On March 10, 2021, we announced a special non-recurring cash dividend of $1.00 per common share in an aggregate amount of $19.9 million that was paid on April 5, 2021, to shareholders of record on March 29, 2021. In accordance with the provisions of our 2012 Stock Incentive Plan (the "2012 Incentive Plan"), as a result of the special dividend we are required to make the participant's original grant whole by preventing either dilution or enlargement of the benefits or potential benefits intended by the original grant. The 2012 Incentive Plan provides our Compensation Committee with the discretion to meet this requirement. See further discussion in the Share-Based Compensation section of this Note. The declaration of future dividends is subject to the discretion of our Board of Directors and will depend upon various factors, including our earnings, financial condition, restrictions imposed by any indebtedness that may be outstanding, cash requirements, future prospects and other factors deemed relevant by our Board of Directors. Share Repurchase Program On March 10, 2021, we announced a $15.0 million common share repurchase program. The repurchases may be made from time to time as market conditions warrant and are subject to regulatory considerations. At September 30, 2021, the remaining balance available for repurchases under the program was $9.0 million. Share-Based Compensation During the year ended December 31, 2012, our shareholders adopted and approved the Nature’s Sunshine Products, Inc. 2012 Stock Incentive Plan. The 2012 Incentive Plan provides for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock, restricted stock units, dividend equivalent rights, performance awards, stock awards and other stock-based awards. The Compensation Committee of the Board of Directors has authority and discretion to determine the type of award, as well as the amount, terms and conditions of each award under the 2012 Incentive Plan, subject to the limitations of the 2012 Incentive Plan. A total of 1,500,000 shares of our common stock were originally authorized for the granting of awards under the 2012 Incentive Plan. In 2015, our shareholders approved an amendment to the 2012 Incentive Plan, to increase the number of shares of common stock reserved for issuance by 1,500,000 shares. On May 5, 2021, our shareholders approved the Amended and Restated 2012 Stock Incentive Plan, which among other amendments, increased the number of shares of common stock reserved for issuance by 2,000,000 shares. The number of shares available for awards, as well as the terms of outstanding awards, are subject to adjustment as provided in the Amended and Restated 2012 Incentive Plan for stock splits, stock dividends, recapitalizations and other similar events. We have also maintained a stock incentive plan, which was approved by shareholders in 2009 (the “2009 Incentive Plan"), which provided for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock, restricted stock units, dividend equivalent rights, performance awards, stock awards and other stock-based awards. As of September 30, 2021, there were no outstanding awards under the 2009 Incentive Plan. Stock Options Our outstanding stock options include time-based stock options, which vest over differing periods of time ranging from the date of issuance to up to 48 months from the option grant date, and performance-based stock options, which have already vested upon achieving operating income margins of six, eight and ten percent as reported in four of five consecutive quarters over the term of the options. Stock option activity for the nine-month period ended September 30, 2021, is as follows (amounts in thousands, except per share information): Number of Weighted Average Weighted Average Options outstanding at December 31, 2020 226 $ 12.10 $ 5.42 Granted — — — Forfeited or canceled — — — Exercised (53) 12.00 6.61 Options outstanding at September 30, 2021 173 $ 12.13 $ 5.05 There was no share-based compensation expense for the three- and nine-month periods ended September 30, 2021 and 2020. As of September 30, 2021 and December 31, 2020, there was no unrecognized share-based compensation expense related to the grants described above. As a result of the special dividend, we issued 4,300 shares to outstanding option holders as dividend equivalents in order to keep the participant's original grant whole. Because this modification was required under the provisions of our stock incentive plans, no additional share-based compensation expense was recorded. At September 30, 2021, the aggregate intrinsic value of outstanding and exercisable stock options to purchase 173,000 shares of common stock was $0.5 million. At December 31, 2020, the aggregate intrinsic value of outstanding and exercisable options to purchase 226,000 shares of common stock was $0.7 million. For the nine-month periods ended September 30, 2021 and 2020, we issued 53,000 and 41,000 shares of common stock upon the exercise of stock options at an average exercise price of $12.00 and $7.92 per share, respectively. The aggregate intrinsic value of options exercised during the nine-month periods ended September 30, 2021 and 2020, was $0.4 million and $0.1 million, respectively. For the nine-month periods ended September 30, 2021 and 2020, the Company recognized $0.2 million and $0.1 million of tax benefits from the exercise of stock options, respectively. As of September 30, 2021 and December 31, 2020, we did not have any unvested performance-based stock options outstanding. Restricted Stock Units Our outstanding restricted stock units (“RSUs”), include time-based RSUs, which vest over differing periods of time ranging from 12 months to up to 36 months from the RSU grant date, as well as performance-based RSUs, which vest upon achieving targets relating to revenue and earnings growth, earnings-per-share, and/or stock price levels. RSUs granted to members of the Board of Directors contain a restriction period in which the shares are not issued until two years after vesting. At September 30, 2021 and December 31, 2020, there were 94,000 and 82,000 vested RSUs, respectively, granted to the Board of Directors with an accompanying restriction period. Restricted stock unit activity for the nine-month period ended September 30, 2021, is as follows (amounts in thousands, except per share information): Number of Weighted Average Restricted Stock Units outstanding at December 31, 2020 1,179 $ 6.18 Granted 306 13.48 Forfeited (94) 6.91 Issued (519) 6.38 Restricted Stock Units outstanding at September 30, 2021 872 8.55 During the nine-month period ended September 30, 2021, we granted 306,000 RSUs under the 2012 Incentive Plan to the Board of Directors, executive officers and other employees, which were comprised of both time-based RSUs and share-priced performance-based RSUs. The time-based RSUs were issued with a weighted-average grant date fair value of $18.05 per share and vest in annual installments over a three-year period from the grant date. The share-priced performance-based RSUs were issued with a weighted-average grant date fair value of $13.87 per share and vest upon achieving share-priced targets over a three-year period from the grant date. Except for share-priced performance RSUs, RSUs are valued at market value on the date of grant, which is the grant date share price discounted for expected dividend payments during the vesting period. For RSUs with post-vesting restrictions, a Finnerty Model was utilized to calculate a valuation discount from the market value of common shares reflecting the restriction embedded in the RSUs preventing the sale of the underlying shares over a certain period of time. Using assumptions previously determined for the application of the option pricing model at the valuation date, the Finnerty Model discount for lack of marketability is approximately 12.7 percent for a common share. Share-price performance-based RSUs were estimated using the Monte Carlo simulation model. The Monte Carlo simulation model utilizes multiple input variables to estimate the probability that market conditions will be achieved. Our assumptions include a performance period of three years, expected volatility of between 50.0 percent and 54.70 percent, and a range of risk-free rates between 0.3 percent and 2.9 percent. Share-based compensation expense for RSUs for the three-month periods ended September 30, 2021 and 2020, was approximately $0.6 million and $0.5 million, respectively. Share-based compensation expense from RSUs for the nine-month periods ended September 30, 2021 and 2020, was approximately $1.6 million and $1.4 million, respectively. As of September 30, 2021 and December 31, 2020, the unrecognized share-based compensation expense related to the grants described above, excluding incentive awards discussed below, was $2.0 million and $1.3 million, respectively. The remaining compensation expense is expected to be recognized over the weighted average period of approximately 0.8 years. Share-based compensation expense related to performance-based RSUs for the three-month periods ended September 30, 2021 and 2020, was $0.3 million and $0.5 million, respectively. Share-based compensation expense related to performance-based RSUs for the nine-month periods ended September 30, 2021 and 2020, was $1.2 million and $0.8 million, respectively. Should we attain all of the metrics related to performance-based RSU grants, we would, and expect to, recognize up to $1.8 million of potential share-based compensation expense. As a result of the special dividend, we issued 22,000 time-based RSUs and 26,200 performance-based RSUs that mirror the original grant time and performance-based vesting targets and requirements as dividend equivalents in order to keep the participant's original grant whole. These awards are included in the granted share total in the table above. Because this modification was required under the provisions of our stock incentive plans, no additional share-based compensation expense was recorded.

Segment Information

Segment Information	9 Months Ended
	Sep. 30, 2021
Segment Reporting [Abstract]
Segment Information	Segment Information We have four business segments (Asia, Europe, North America, and Latin America and Other) based primarily upon the geographic region where each segment operates, as well as the internal organization of our officers and their responsibilities. Each of the geographic segments operate under the Nature’s Sunshine Products and Synergy® WorldWide brands. The Latin America and Other segment includes our wholesale business in which we sell products to various locally-managed entities independent of the Company that we have granted distribution rights for the relevant market. Net sales for each segment have been reduced by intercompany sales as they are not included in the measure of segment profit or loss reviewed by the chief executive officer. We evaluate performance based on contribution margin by segment before consideration of certain inter-segment transfers and expenses. Reportable business segment information is as follows (dollar amounts in thousands): Three Months Ended Nine Months Ended 2021 2020 2021 2020 Net sales: Asia $ 48,417 $ 38,099 $ 127,708 $ 101,814 Europe 21,813 18,006 65,468 54,098 North America 37,738 37,557 112,872 110,785 Latin America and Other 6,778 6,588 20,097 16,765 Total net sales 114,746 100,250 326,145 283,462 Contribution margin (1): Asia 21,421 17,981 55,203 48,560 Europe 6,959 5,954 20,343 17,987 North America 17,193 12,065 48,892 38,388 Latin America and Other 3,961 2,765 11,355 7,161 Total contribution margin 49,534 38,765 135,793 112,096 Selling, general and administrative expenses (2) 39,528 33,294 108,666 92,863 Operating income 10,006 5,471 27,127 19,233 Other income (loss), net (886) 671 (2,290) (230) Income before provision for income taxes $ 9,120 $ 6,142 $ 24,837 $ 19,003 _________________________________________ (1) Contribution margin consists of net sales less cost of sales and volume incentives expense. (2) Service fees in China totaled $5.2 million and $11.7 million for the three and nine-month periods ended September 30, 2021, respectively, compared to $3.2 million and $8.0 million for the three and nine-month periods ended September 30, 2020. These service fees are included in selling, general and administrative expenses. From an individual country perspective, the United States and South Korea comprise 10 percent or more of consolidated net sales for the three and nine-month periods ended September 30, 2021 and 2020, as follows (dollar amounts in thousands): Three Months Ended Nine Months Ended 2021 2020 2021 2020 Net sales: United States $ 34,960 $ 35,062 $ 104,258 $ 103,048 South Korea 15,985 16,592 48,340 47,447 Other 63,801 48,596 173,547 132,967 $ 114,746 $ 100,250 $ 326,145 $ 283,462 Net sales generated by each of our product lines is set forth below (dollar amounts in thousands): Three Months Ended Nine Months Ended 2021 2020 2021 2020 Asia General health $ 13,150 $ 10,055 $ 37,140 $ 27,364 Immune 463 85 1,048 465 Cardiovascular 13,018 10,622 35,181 29,284 Digestive 10,427 9,935 25,045 24,482 Personal care 4,201 2,575 12,015 7,457 Weight management 7,158 4,827 17,279 12,762 48,417 38,099 127,708 101,814 Europe General health $ 9,308 $ 7,725 $ 28,447 $ 22,501 Immune 2,285 1,510 6,119 5,324 Cardiovascular 2,774 2,581 8,602 7,693 Digestive 5,700 4,541 16,807 13,254 Personal care 1,167 1,023 3,592 3,492 Weight management 579 626 1,901 1,834 21,813 18,006 65,468 54,098 North America General health $ 16,573 $ 15,839 $ 49,192 $ 46,190 Immune 5,056 5,790 14,031 18,637 Cardiovascular 4,171 4,138 12,406 11,984 Digestive 9,079 8,635 28,558 24,734 Personal care 1,978 1,963 5,631 5,867 Weight management 881 1,192 3,054 3,373 37,738 37,557 112,872 110,785 Latin America and Other General health $ 1,959 $ 2,038 $ 5,807 $ 5,002 Immune 806 837 2,314 2,326 Cardiovascular 448 429 1,351 1,070 Digestive 2,941 2,682 8,813 7,008 Personal care 406 384 1,149 848 Weight management 218 218 663 511 6,778 6,588 20,097 16,765 $ 114,746 $ 100,250 $ 326,145 $ 283,462 From an individual country perspective, only the United States comprised 10 percent or more of consolidated property, plant and equipment as follows (dollar amounts in thousands): September 30, December 31, Property, plant and equipment: United States $ 48,176 $ 50,025 Other 4,362 4,330 Total property, plant and equipment, net $ 52,538 $ 54,355 Total assets per segment is set forth below (dollar amounts in thousands): September 30, December 31, Assets: Asia $ 96,522 $ 82,572 Europe 17,931 16,398 North America 117,215 142,324 Latin America and Other 8,084 8,204 Total assets $ 239,752 $ 249,498

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2021
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes For the three months ended September 30, 2021 and 2020, our provision (benefit) for income taxes, as a percentage of income before income taxes was 40.2 percent and (16.7) percent, respectively, compared with a U.S. federal statutory rate of 21.0 percent. For the nine months ended September 30, 2021 and 2020, our provision for income taxes, as a percentage of income before income taxes was 34.0 percent and 14.2 percent, respectively, compared with a U.S. federal statutory rate of 21.0 percent. The difference between the effective tax rate and the U.S. federal statutory tax rate for the three and nine months ended September 30, 2021, was primarily attributed to an increase in tax liability associated with transfer pricing adjustments, non-deductible executive compensation, and net unfavorable foreign tax related items, partially offset by favorable deductions for stock compensation. The difference between the effective tax rate and the U.S. federal statutory tax rate for the three months ended September 30, 2020, was primarily attributed to a decrease in tax liability associated with uncertain tax positions and release of valuation allowance for deferred tax assets expected to be utilized in the prior year. The difference between the effective tax rate and the U.S. federal statutory tax rate for the nine months ended September 30, 2020, was primarily attributed to a decrease in tax liability associated with uncertain tax positions and release of valuation allowance for deferred tax assets expected to be utilized in the prior year, partially offset by transfer pricing adjustments and foreign losses during that period that were not expected to provide future tax benefit, as well as net unfavorable foreign tax related items. The difference between the effective tax rate for the three and nine months ended September 30, 2021 compared to September 30, 2020 is primarily caused by an increase in the current period tax liability associated with transfer pricing adjustments and non-deductible executive compensation, partially offset by favorable deductions for stock compensation in the current period, as well as decreases in prior period uncertain tax positions and valuation allowances which did not repeat in the current period. As the U.S. Department of the Treasury is working on finalizing Treasury Regulations with respect to the Tax Cuts and Jobs Act (Tax Reform Act), future changes could likewise affect recorded deferred tax assets and liabilities in later periods. Management is not aware of any such additional changes that would have a material effect on our results of operations, cash flows or financial position. Our U.S. federal income tax returns for 2017 through 2020 are open to examination for federal tax purposes. We have several foreign tax jurisdictions with open tax years from 2014 through 2020. As of September 30, 2021 and December 31, 2020, we have accrued $5,000 and $0.1 million, respectively, related to unrecognized tax positions. Interim income taxes are based on an estimated annualized effective tax rate applied to the respective quarterly periods, adjusted for discrete tax items in the period in which they occur. Although we believe our tax estimates are reasonable, we can make no assurance that the final tax outcome of these matters will not be different from that which we have reflected in our historical income tax provisions and accruals. Such differences could have a material impact on our income tax provision and operating results in the period in which we make such determination.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Legal Proceedings We are party to various legal proceedings and disputes. Management cannot predict the ultimate outcome of these matters, individually or in the aggregate, or their resulting effect on our business, financial position, results of operations or cash flows as litigation and related matters are subject to inherent uncertainties, and unfavorable rulings could occur. Were an unfavorable outcome to occur, there exists the possibility of a material adverse impact on our business, financial position, results of operations, or cash flows for the period in which the ruling occurs and/or future periods. We maintain product liability, general liability and excess liability insurance coverage. However, insurance may not continue to be available at an acceptable cost to us, such coverage may not be sufficient to cover one or more large claims, or the insurers may successfully disclaim coverage as to a pending or future claim. Non-Income Tax Contingencies We have reserved for certain state sales and use tax and foreign non-income tax contingencies based on the likelihood of an obligation in accordance with accounting guidance for probable loss contingencies. Loss contingency provisions are recorded for probable losses at management’s best estimate of a loss, or when a best estimate cannot be made, a minimum loss contingency amount is recorded. We provide provisions for potential payments of tax to various tax authorities for contingencies related to non-income tax matters, including value-added taxes and sales tax. We provide provisions for U.S. state sales taxes in each of the states where we have nexus. As of September 30, 2021 and December 31, 2020, accrued liabilities were $0.2 million and $0.2 million, respectively, related to non-income tax contingencies. While we believe that the assumptions and estimates used to determine contingent liabilities are reasonable, the ultimate outcome of these matters cannot presently be determined. We believe future payments related to these matters could range from $0 to approximately $2.5 million. Other Litigation

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2021
Related Party Transactions [Abstract]
Related Party Transactions	Related Party TransactionsDuring the three and nine months ended September 30, 2021 and 2020, our joint venture in China, owned 80 percent by us and 20 percent by a wholly owned subsidiary of Fosun Pharma, did not borrow any amounts from the Company or our joint venture partner. As of September 30, 2021 and December 31, 2020 outstanding borrowings by NSP China from the Company were $2.4 million and $4.8 million, respectively. As of September 30, 2021 and December 31, 2020 outstanding borrowings by NSP China from our joint venture partner were $0.6 million and $1.2 million, respectively. These notes are payable in less than one year and bear interest of 3.0 percent. The notes between NSP China and the Company eliminate in consolidation.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2021
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements The fair value of a financial instrument is the amount that could be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Financial assets are marked to bid prices and financial liabilities are marked to offer prices. Fair value measurements do not include transaction costs. A fair value hierarchy is used to prioritize the quality and reliability of the information used to determine fair values of each financial instrument. Categorization within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. The fair value hierarchy is defined into the following three categories: Level 1: Quoted market prices in active markets for identical assets or liabilities. Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data. Level 3: Unobservable inputs that are not corroborated by market data. The following table presents our hierarchy for our assets, measured at fair value on a recurring basis, as of September 30, 2021 (dollar amounts in thousands): Level 1 Level 2 Level 3 Quoted Prices Significant Significant Total Investment securities - trading $ 950 $ — $ — $ 950 Total assets measured at fair value on a recurring basis $ 950 $ — $ — $ 950 The following table presents our hierarchy for our assets, measured at fair value on a recurring basis, as of December 31, 2020 (dollar amounts in thousands): Level 1 Level 2 Level 3 Quoted Prices Significant Significant Total Investment securities - trading $ 989 $ — $ — $ 989 Total assets measured at fair value on a recurring basis $ 989 $ — $ — $ 989 Investment securities - trading — Our trading portfolio consists of various marketable securities that are valued using quoted prices in active markets. For the nine months ended September 30, 2021, and for the year ended December 31, 2020, there were no fair value measurements using significant other observable inputs (Level 2) or significant unobservable inputs (Level 3). The carrying amounts reflected on the condensed consolidated balance sheets for cash and cash equivalents, accounts receivable, and accounts payable approximate fair value due to their short-term nature. The carrying value of our debt approximates fair value due to its recent acquisition and short maturity. During the nine months ended September 30, 2021 and 2020, we did not have any re-measurements of non-financial assets at fair value on a nonrecurring basis subsequent to their initial recognition.

Revenue Recognition

Revenue Recognition	9 Months Ended
	Sep. 30, 2021
Revenue from Contract with Customer [Abstract]
Revenue Recognition	Revenue Recognition Revenue Recognition Net sales include products and shipping and handling charges, net of estimates for product returns and any related sales incentives or rebates based upon historical information and current trends. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring products. All revenue is recognized when the Company satisfies its performance obligations under the contract. We recognize revenue by transferring the promised products to the customer, with revenue recognized at shipping point, the point in time the customer obtains control of the products. The majority of our contracts have a single performance obligation and are short term in nature. Contracts with multiple performance obligations are insignificant. Sales taxes and value-added taxes in the United States and foreign jurisdictions that are collected from customers and remitted to governmental authorities are accounted for on a net basis and therefore are excluded from net sales. Amounts received for unshipped merchandise are recorded as deferred revenue. Amounts for membership fees are deferred and amortized as revenue over the life of the membership, primarily one year. A reserve for product returns is recorded based upon historical experience and current trends. We allow independent consultants to return the unused portion of products within ninety days of purchase if they are not satisfied with the product. In some of our markets, the requirements to return product are more restrictive. From time to time, our U.S. operations extend short-term credit associated with product promotions. In addition, for certain of our international operations, we offer credit terms consistent with industry standards within the country of operation. Volume incentives and other sales incentives or rebates are a significant part of our direct sales marketing program and represent commission payments made to independent consultants. These payments are designed to provide incentives for reaching higher sales levels. The amount of volume incentive expense recognized is determined based upon the amount of qualifying purchases in a given month and recorded as volume incentive expense. Payments to independent consultants for sales incentives or rebates related to their own purchases are recorded as a reduction of revenue. Some payments for sales incentives are processed daily; while others, including rebates, are calculated monthly based upon qualifying sales. Contract Liabilities - Customer Loyalty Programs Historically, we have offered loyalty point programs which allowed customers to earn loyalty points on personal orders. Loyalty points were recorded as contract liabilities in deferred revenue. These programs were accounted for as a reduction in the transaction price and generally recognized as points that were redeemed for additional products. During the year ended December 31, 2020 these programs were discontinued. As of September 30, 2021, there were no outstanding loyalty points. Disaggregation of Revenue Our products are grouped into six principal categories: general health, immune, cardiovascular, digestive, personal care and weight management. We have four business segments that are based primarily upon the geographic region where each segment operates. Each of the geographic segments operate under the Nature’s Sunshine Products and Synergy® WorldWide brands. See Note 7, Segment Information, for further information on our reportable segments and presentation of disaggregated revenue by reportable segment and product category. Practical Expedients and Exemptions We have made the accounting policy election to treat shipping and handling as a fulfillment activity rather than a promised service under Topic 606. We generally expense volume incentives when incurred because the amortization period would have been one year or less. All of our contracts with customers have a duration of less than one year. The value of any unsatisfied performance obligations is insignificant.

Basis of Presentation (Policies

Basis of Presentation (Policies)	9 Months Ended
	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation We are a natural health and wellness company primarily engaged in the manufacture and sale of nutritional and personal care products. We are a Utah corporation with our principal place of business in Lehi, Utah, and sell our products to a sales force of independent consultants who use the products themselves or resell them to consumers.
Principles of Consolidation	Principles of Consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. The unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany accounts and transactions are eliminated in consolidation. In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting of normal recurring accruals), considered necessary for a fair presentation of our financial information as of September 30, 2021, and for the three and nine-month periods ended September 30, 2021 and 2020. The results of operations of any interim period are not necessarily indicative of the results of operations to be expected for the year ending December 31, 2021. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2020 as amended by Form 10-K/A on July 9, 2021.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in accordance with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities, in these financial statements and accompanying notes. Actual results could differ from these estimates due to the uncertainty around the magnitude and duration of the COVID-19 pandemic, as well as other factors and those differences could have a material effect on our financial position and results of operations.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In December 2019, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. This ASU eliminates certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating taxes during the quarters and the recognition of deferred tax liabilities for outside basis differences. The amendments in this update are effective for reporting periods beginning after December 15, 2020. The adoption of this ASU did not have a significant impact on our Consolidated Financial Statements. In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting. This ASU provides optional guidance for a limited period of time to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting. The amendments in this update are elective and subject to meeting certain criteria, that have contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. This could affect balances of right of use assets, lease liabilities, and notes payables. The amendments in this update are effective as of March 12, 2020 through December 21, 2022. The adoption of this ASU is not expected to have a significant impact on our Consolidated Financial Statements.

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Sep. 30, 2021
Inventory Disclosure [Abstract]
Schedule of composition of inventories	The composition of inventories is as follows (dollar amounts in thousands): September 30, December 31, Raw materials $ 19,603 $ 13,956 Work in progress 1,619 1,351 Finished goods 36,154 32,376 Total inventories $ 57,376 $ 47,683

Net Income Per Share (Tables)

Net Income Per Share (Tables)	9 Months Ended
	Sep. 30, 2021
Earnings Per Share [Abstract]
Schedule of reconciliation of the numerator and denominator of Basic EPS to the numerator and denominator of Diluted EPS	Following is a reconciliation of the numerator and denominator of Basic EPS to the numerator and denominator of Diluted EPS for the three and nine months ended September 30, 2021 and 2020 (dollar and share amounts in thousands, except for per share information): Three Months Ended Nine Months Ended 2021 2020 2021 2020 Net income attributable to common shareholders $ 4,858 $ 6,755 $ 15,414 $ 15,471 Basic weighted average shares outstanding 19,894 19,533 19,896 19,493 Basic earnings per share attributable to common shareholders $ 0.24 $ 0.35 $ 0.77 $ 0.79 Diluted shares outstanding: Basic weighted-average shares outstanding 19,894 19,533 19,896 19,493 Stock-based awards 481 326 396 327 Diluted weighted-average shares outstanding 20,375 19,859 20,292 19,820 Diluted earnings per share attributable to common shareholders $ 0.24 $ 0.34 $ 0.76 $ 0.78 Dilutive shares excluded from diluted-per-share amounts: Stock options 460 791 460 791 Anti-dilutive shares excluded from diluted-per-share amounts: Stock options — 199 — 199

Capital Transactions (Tables)

Capital Transactions (Tables)	9 Months Ended
	Sep. 30, 2021
Equity [Abstract]
Schedule of stock option activity	Stock option activity for the nine-month period ended September 30, 2021, is as follows (amounts in thousands, except per share information): Number of Weighted Average Weighted Average Options outstanding at December 31, 2020 226 $ 12.10 $ 5.42 Granted — — — Forfeited or canceled — — — Exercised (53) 12.00 6.61 Options outstanding at September 30, 2021 173 $ 12.13 $ 5.05
Schedule of restricted stock unit activity	Restricted stock unit activity for the nine-month period ended September 30, 2021, is as follows (amounts in thousands, except per share information): Number of Weighted Average Restricted Stock Units outstanding at December 31, 2020 1,179 $ 6.18 Granted 306 13.48 Forfeited (94) 6.91 Issued (519) 6.38 Restricted Stock Units outstanding at September 30, 2021 872 8.55

Segment Information (Tables)

Segment Information (Tables)	9 Months Ended
	Sep. 30, 2021
Segment Reporting [Abstract]
Schedule of reportable business segment information	Reportable business segment information is as follows (dollar amounts in thousands): Three Months Ended Nine Months Ended 2021 2020 2021 2020 Net sales: Asia $ 48,417 $ 38,099 $ 127,708 $ 101,814 Europe 21,813 18,006 65,468 54,098 North America 37,738 37,557 112,872 110,785 Latin America and Other 6,778 6,588 20,097 16,765 Total net sales 114,746 100,250 326,145 283,462 Contribution margin (1): Asia 21,421 17,981 55,203 48,560 Europe 6,959 5,954 20,343 17,987 North America 17,193 12,065 48,892 38,388 Latin America and Other 3,961 2,765 11,355 7,161 Total contribution margin 49,534 38,765 135,793 112,096 Selling, general and administrative expenses (2) 39,528 33,294 108,666 92,863 Operating income 10,006 5,471 27,127 19,233 Other income (loss), net (886) 671 (2,290) (230) Income before provision for income taxes $ 9,120 $ 6,142 $ 24,837 $ 19,003 _________________________________________ (1) Contribution margin consists of net sales less cost of sales and volume incentives expense.
Schedule of consolidated net sales revenue by geographical locations	From an individual country perspective, the United States and South Korea comprise 10 percent or more of consolidated net sales for the three and nine-month periods ended September 30, 2021 and 2020, as follows (dollar amounts in thousands): Three Months Ended Nine Months Ended 2021 2020 2021 2020 Net sales: United States $ 34,960 $ 35,062 $ 104,258 $ 103,048 South Korea 15,985 16,592 48,340 47,447 Other 63,801 48,596 173,547 132,967 $ 114,746 $ 100,250 $ 326,145 $ 283,462
Schedule of revenue generated by each of the Company's product lines	Net sales generated by each of our product lines is set forth below (dollar amounts in thousands): Three Months Ended Nine Months Ended 2021 2020 2021 2020 Asia General health $ 13,150 $ 10,055 $ 37,140 $ 27,364 Immune 463 85 1,048 465 Cardiovascular 13,018 10,622 35,181 29,284 Digestive 10,427 9,935 25,045 24,482 Personal care 4,201 2,575 12,015 7,457 Weight management 7,158 4,827 17,279 12,762 48,417 38,099 127,708 101,814 Europe General health $ 9,308 $ 7,725 $ 28,447 $ 22,501 Immune 2,285 1,510 6,119 5,324 Cardiovascular 2,774 2,581 8,602 7,693 Digestive 5,700 4,541 16,807 13,254 Personal care 1,167 1,023 3,592 3,492 Weight management 579 626 1,901 1,834 21,813 18,006 65,468 54,098 North America General health $ 16,573 $ 15,839 $ 49,192 $ 46,190 Immune 5,056 5,790 14,031 18,637 Cardiovascular 4,171 4,138 12,406 11,984 Digestive 9,079 8,635 28,558 24,734 Personal care 1,978 1,963 5,631 5,867 Weight management 881 1,192 3,054 3,373 37,738 37,557 112,872 110,785 Latin America and Other General health $ 1,959 $ 2,038 $ 5,807 $ 5,002 Immune 806 837 2,314 2,326 Cardiovascular 448 429 1,351 1,070 Digestive 2,941 2,682 8,813 7,008 Personal care 406 384 1,149 848 Weight management 218 218 663 511 6,778 6,588 20,097 16,765 $ 114,746 $ 100,250 $ 326,145 $ 283,462
Schedule of consolidated property, plant and equipment by geographical locations	From an individual country perspective, only the United States comprised 10 percent or more of consolidated property, plant and equipment as follows (dollar amounts in thousands): September 30, December 31, Property, plant and equipment: United States $ 48,176 $ 50,025 Other 4,362 4,330 Total property, plant and equipment, net $ 52,538 $ 54,355
Schedule of assets per segment	Total assets per segment is set forth below (dollar amounts in thousands): September 30, December 31, Assets: Asia $ 96,522 $ 82,572 Europe 17,931 16,398 North America 117,215 142,324 Latin America and Other 8,084 8,204 Total assets $ 239,752 $ 249,498

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2021
Fair Value Disclosures [Abstract]
Schedule of the Company's hierarchy for assets measured at fair value on a recurring basis	The following table presents our hierarchy for our assets, measured at fair value on a recurring basis, as of September 30, 2021 (dollar amounts in thousands): Level 1 Level 2 Level 3 Quoted Prices Significant Significant Total Investment securities - trading $ 950 $ — $ — $ 950 Total assets measured at fair value on a recurring basis $ 950 $ — $ — $ 950 The following table presents our hierarchy for our assets, measured at fair value on a recurring basis, as of December 31, 2020 (dollar amounts in thousands): Level 1 Level 2 Level 3 Quoted Prices Significant Significant Total Investment securities - trading $ 989 $ — $ — $ 989 Total assets measured at fair value on a recurring basis $ 989 $ — $ — $ 989

Basis of Presentation (Details)

Basis of Presentation (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Noncontrolling Interest [Line Items]
Increase (decrease) in noncontrolling interest	$ 600,000	$ 400,000	$ 1,000,000	$ 800,000
Noncontrolling interest	2,838,000		2,838,000		$ 1,848,000
Restructuring charges	0	$ 0	48,000	$ 100,000
Accrued Severance and Rent Costs
Noncontrolling Interest [Line Items]
Restructuring Reserve	$ 0		$ 0		$ 400,000

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Inventory Disclosure [Abstract]
Raw materials	$ 19,603	$ 13,956
Work in progress	1,619	1,351
Finished goods	36,154	32,376
Total inventories	$ 57,376	$ 47,683

Investment Securities - Tradi_2

Investment Securities - Trading (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Investments, Debt and Equity Securities [Abstract]
Trading securities portfolio	$ 950		$ 950		$ 989
Debt securities, trading, realized gains (losses)	$ (4)	$ 45	$ 62	$ 41

Revolving Credit Facility and_2

Revolving Credit Facility and Other Obligations (Details)	Nov. 19, 2020USD ($)payment	Jun. 11, 2020USD ($)borrowing	Sep. 30, 2021USD ($)	Dec. 31, 2020	Apr. 21, 2020USD ($)	Jul. 11, 2017USD ($)
Revolving credit facility | Bank of America Credit Agreement
Long-term debt
Maximum borrowing capacity						$ 25,000,000
Potential increase in maximum borrowing capacity		$ 15,000,000
Number of separate increases | borrowing		3
Potential increase in maximum borrowing capacity, per occurrence		$ 5,000,000
Annual commitment fee		0.25%
Long-term line of credit			$ 0
Revolving credit facility | LIBOR | Bank of America Credit Agreement
Long-term debt
Margin on variable rate		2.25%
Effective interest rate			2.33%	3.00%
Revolving credit facility | LIBOR | Bank of America Credit Agreement | Minimum
Long-term debt
Margin on variable rate		0.75%
Revolving credit facility | Indicative Index | Banc of America Leasing and Capital Credit Agreement
Long-term debt
Effective interest rate			3.00%
Line of Credit | Banc of America Leasing and Capital Credit Agreement
Long-term debt
Maximum borrowing capacity					$ 6,000,000
Number of monthly payments | payment	36
Debt Instrument, Periodic Payment, Principal	$ 100,000
Long-term line of credit	$ 3,700,000		$ 2,700,000
Line of Credit, Current			$ 1,200,000

Net Income Per Share (Details)

Net Income Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Earnings Per Share [Abstract]
Net income attributable to common shareholders	$ 4,858	$ 6,755	$ 15,414	$ 15,471
Net income attributable to common shareholders	$ 4,858	$ 6,755	$ 15,414	$ 15,471
Basic weighted average shares outstanding (in shares)	19,894	19,533	19,896	19,493
Basic earnings per share attributable to common shareholders (in dollars per share)	$ 0.24	$ 0.35	$ 0.77	$ 0.79
Diluted shares outstanding:
Basic weighted-average shares outstanding (in shares)	19,894	19,533	19,896	19,493
Stock-based awards (in shares)	481	326	396	327
Diluted weighted-average shares outstanding (in shares)	20,375	19,859	20,292	19,820
Diluted earnings per share attributable to common shareholders (in dollars per share)	$ 0.24	$ 0.34	$ 0.76	$ 0.78
Dilutive shares excluded from diluted-per-share amounts:
Stock options (in shares)	460	791	460	791
Anti-dilutive shares excluded from diluted-per-share amounts:
Stock options (in shares)	0	199	0	199

Capital Transactions - Narrativ

Capital Transactions - Narrative (Details) - USD ($)	May 05, 2021	Apr. 05, 2021	Mar. 10, 2021	Sep. 30, 2021	Mar. 31, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2015	Dec. 31, 2020	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, dividends (in dollars per share)		$ 1
Dividends, common stock, cash		$ 19,900,000			$ 19,858,000
Stock repurchase program, authorized amount			$ 15,000,000
Stock repurchase program, remaining authorized repurchase amount				$ 9,000,000			$ 9,000,000
2012 Stock Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized under the plan (in shares)											1,500,000
Additional number of shares authorized under the plan (in shares)	2,000,000								1,500,000
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense			$ 0	0		$ 0	0	$ 0
Unrecognized share-based compensation expense				$ 0			$ 0			$ 0
Stock dividends (in shares)			4,300
Options outstanding (in shares)				173,000			173,000			226,000
Aggregate intrinsic value, outstanding				$ 500,000			$ 500,000			$ 700,000
Exercised (in shares)							53,000	41,000
Exercised (in dollars per share)							$ 12	$ 7.92
Aggregate intrinsic values of options exercised							$ 400,000	$ 100,000
Tax benefit from the exercise of stock options							$ 200,000	100,000
Weighted-average grant date fair value (in dollars per share)							$ 0
Time-based stock options | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period							48 months
Performance based stock options operating income margins
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Operating income margin, one (as a percent)							6.00%
Operating income margin, two (as a percent)							8.00%
Operating income margin, three (as a percent)							10.00%
Unvested stock options outstanding (in shares)				0			0			0
Performance based stock options operating income margins | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award performance period							1 year
Performance based stock options operating income margins | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award performance period							1 year 3 months
RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense			$ 0	$ 600,000		500,000	$ 1,600,000	$ 1,400,000
Unrecognized share-based compensation expense				$ 2,000,000			$ 2,000,000			$ 1,300,000
Discount for lack of marketability							12.70%
Award performance period							3 years
Weighted-average period over which the remaining compensation cost is expected to be recognized							9 months 18 days
Minimum withholding requirements (in shares)							150,000	41,000
RSUs | 2012 Stock Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)							306,000
RSUs | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility (as a percent)							50.00%
Risk-free interest rate (as a percent)							0.30%
RSUs | Minimum | 2012 Stock Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period							12 months
RSUs | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility (as a percent)							54.70%
Risk-free interest rate (as a percent)							2.90%
RSUs | Maximum | 2012 Stock Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period							36 months
RSUs | Director | 2012 Stock Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restriction period for issuance of shares							2 years
Nonvested subject to restriction period (in shares)				94,000			94,000			82,000
Time-Based Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)			22,000
Time-Based Restricted Stock Units (RSUs) | 2012 Stock Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period							3 years
Weighted-average grant date fair value (in dollars per share)							$ 18.05
Performance-Based Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense				$ 300,000		$ 500,000	$ 1,200,000	$ 800,000
Granted (in shares)			26,200
Performance-Based Restricted Stock Units (RSUs) | 2012 Stock Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average grant date fair value (in dollars per share)							$ 13.87
Performance-Based Restricted Stock Units (RSUs) | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation potential compensation expense to be recognized				$ 1,800,000			$ 1,800,000
Performance-Based Restricted Stock Units (RSUs) | Net Sales and Operating Income Targets | 2012 Stock Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period							3 years

Capital Transactions - Stock Op

Capital Transactions - Stock Option Activity (Details) - Stock options - $ / shares	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Number of Shares
Options outstanding at the beginning of the period (in shares)	226,000
Granted (in shares)	0
Forfeited or canceled (in shares)	0
Exercised (in shares)	(53,000)	(41,000)
Options outstanding at the end of the period (in shares)	173,000
Weighted Average Exercise Price Per Share
Options outstanding at the beginning of the period (in dollars per share)	$ 12.10
Granted (in dollars per share)	0
Forfeited or canceled (in dollars per share)	0
Exercised (in dollars per share)	12	$ 7.92
Options outstanding at the end of the period (in dollars per share)	12.13
Weighted Average Grant Date Fair Value
Options outstanding at the beginning of the period (in dollars per share)	5.42
Granted (in dollars per share)	0
Forfeited or canceled (in dollars per share)	0
Exercised (in dollars per share)	6.61
Options outstanding at the beginning of the period (in dollars per share)	$ 5.05

Capital Transactions - RSU Acti

Capital Transactions - RSU Activity (Details) - 2012 Stock Incentive Plan - RSUs	9 Months Ended
	Sep. 30, 2021$ / sharesshares
Number of Shares
Restricted Stock Units outstanding, beginning balance (in shares) | shares	1,179,000
Granted (in shares) | shares	306,000
Forfeited (in shares) | shares	(94,000)
Issued (in shares) | shares	(519,000)
Restricted Stock Units outstanding, ending balance (in shares) | shares	872,000
Weighted Average Grant Date Fair Value
Restricted Stock Units outstanding, beginning balance (in dollars per share) | $ / shares	$ 6.18
Granted (in dollars per share) | $ / shares	13.48
Forfeited (in dollars per share) | $ / shares	6.91
Issued (in dollars per share) | $ / shares	6.38
Restricted Stock Units outstanding, ending balance (in dollars per share) | $ / shares	$ 8.55

Segment Information (Details)

Segment Information (Details) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2021USD ($)segment	Sep. 30, 2020USD ($)	Dec. 31, 2020USD ($)
Segment information
Number of business segments | segment			4
Net sales:
Total net sales revenue	$ 114,746	$ 100,250	$ 326,145	$ 283,462
Contribution margin:
Total contribution margin	49,534	38,765	135,793	112,096
Selling, general and administrative expenses	39,528	33,294	108,666	92,863
Operating income	10,006	5,471	27,127	19,233
Other income (loss), net	(886)	671	(2,290)	(230)
Income before provision for income taxes	9,120	6,142	24,837	19,003
Total property, plant and equipment, net	52,538		52,538		$ 54,355
Total assets	239,752		239,752		249,498
Asia
Net sales:
Total net sales revenue	48,417	38,099	127,708	101,814
Contribution margin:
Total contribution margin	21,421	17,981	55,203	48,560
Total assets	96,522		96,522		82,572
Asia | General health
Net sales:
Total net sales revenue	13,150	10,055	37,140	27,364
Asia | Immune
Net sales:
Total net sales revenue	463	85	1,048	465
Asia | Cardiovascular
Net sales:
Total net sales revenue	13,018	10,622	35,181	29,284
Asia | Digestive
Net sales:
Total net sales revenue	10,427	9,935	25,045	24,482
Asia | Personal care
Net sales:
Total net sales revenue	4,201	2,575	12,015	7,457
Asia | Weight management
Net sales:
Total net sales revenue	7,158	4,827	17,279	12,762
Europe
Net sales:
Total net sales revenue	21,813	18,006	65,468	54,098
Contribution margin:
Total contribution margin	6,959	5,954	20,343	17,987
Total assets	17,931		17,931		16,398
Europe | General health
Net sales:
Total net sales revenue	9,308	7,725	28,447	22,501
Europe | Immune
Net sales:
Total net sales revenue	2,285	1,510	6,119	5,324
Europe | Cardiovascular
Net sales:
Total net sales revenue	2,774	2,581	8,602	7,693
Europe | Digestive
Net sales:
Total net sales revenue	5,700	4,541	16,807	13,254
Europe | Personal care
Net sales:
Total net sales revenue	1,167	1,023	3,592	3,492
Europe | Weight management
Net sales:
Total net sales revenue	579	626	1,901	1,834
North America
Net sales:
Total net sales revenue	37,738	37,557	112,872	110,785
Contribution margin:
Total contribution margin	17,193	12,065	48,892	38,388
Total assets	117,215		117,215		142,324
North America | General health
Net sales:
Total net sales revenue	16,573	15,839	49,192	46,190
North America | Immune
Net sales:
Total net sales revenue	5,056	5,790	14,031	18,637
North America | Cardiovascular
Net sales:
Total net sales revenue	4,171	4,138	12,406	11,984
North America | Digestive
Net sales:
Total net sales revenue	9,079	8,635	28,558	24,734
North America | Personal care
Net sales:
Total net sales revenue	1,978	1,963	5,631	5,867
North America | Weight management
Net sales:
Total net sales revenue	881	1,192	3,054	3,373
Latin America and Other
Net sales:
Total net sales revenue	6,778	6,588	20,097	16,765
Contribution margin:
Total contribution margin	3,961	2,765	11,355	7,161
Total assets	8,084		8,084		8,204
Latin America and Other | General health
Net sales:
Total net sales revenue	1,959	2,038	5,807	5,002
Latin America and Other | Immune
Net sales:
Total net sales revenue	806	837	2,314	2,326
Latin America and Other | Cardiovascular
Net sales:
Total net sales revenue	448	429	1,351	1,070
Latin America and Other | Digestive
Net sales:
Total net sales revenue	2,941	2,682	8,813	7,008
Latin America and Other | Personal care
Net sales:
Total net sales revenue	406	384	1,149	848
Latin America and Other | Weight management
Net sales:
Total net sales revenue	218	218	663	511
CHINA
Contribution margin:
Selling, general and administrative expenses	5,200	3,200	11,700	8,000
United States
Net sales:
Total net sales revenue	34,960	35,062	104,258	103,048
Contribution margin:
Total property, plant and equipment, net	48,176		48,176		50,025
South Korea
Net sales:
Total net sales revenue	15,985	16,592	48,340	47,447
Other
Net sales:
Total net sales revenue	63,801	$ 48,596	173,547	$ 132,967
Other
Contribution margin:
Total property, plant and equipment, net	$ 4,362		$ 4,362		$ 4,330

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Provision (benefit) for income taxes, as a percentage of income before income taxes	40.20%	(16.70%)	34.00%	14.20%
Liability related to unrecognized tax benefits	$ 5		$ 5		$ 100

Commitments and Contingencies (

Commitments and Contingencies (Details)	9 Months Ended
	Sep. 30, 2021USD ($)claim	Dec. 31, 2020USD ($)
Value-added tax assessments and other civil litigation
Commitments and contingencies
Minimum number of claims that the Company's insurance coverage may not be sufficient to cover | claim	1
Provision for losses	$ 0
Non-Income Tax Contingencies
Commitments and contingencies
Accrued liabilities	200,000	$ 200,000
Minimum | Value-added tax assessments and other civil litigation
Commitments and contingencies
Estimate of possible loss	0
Minimum | Non-Income Tax Contingencies
Commitments and contingencies
Estimate of possible loss	0
Maximum | Value-added tax assessments and other civil litigation
Commitments and contingencies
Estimate of possible loss	300,000
Maximum | Non-Income Tax Contingencies
Commitments and contingencies
Estimate of possible loss	2,500,000
Pending Litigation
Commitments and contingencies
Accrued liabilities	$ 500,000	$ 500,000

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
China Joint Venture Member
Related Party Transaction [Line Items]
Joint venture ownership	80.00%		80.00%
China Joint Venture Member | Fosun Pharma Member
Related Party Transaction [Line Items]
Joint venture ownership, noncontrolling party		20.00%		20.00%
NSP China | Subsidiaries
Related Party Transaction [Line Items]
Notes receivable, related parties, current	$ 2,400,000		$ 2,400,000		$ 4,800,000
NSP China | Subsidiaries | Company's Joint Venture Partner
Related Party Transaction [Line Items]
Notes receivable, related parties, current	600,000		600,000		$ 1,200,000
NSP China | Subsidiaries | Notes Receivable
Related Party Transaction [Line Items]
Related party transaction, amount	$ 0		$ 0
Related party transaction, rate			3.00%
NSP China | Subsidiaries | Notes Receivable | Company's Joint Venture Partner
Related Party Transaction [Line Items]
Related party transaction, amount		$ 0		$ 0

Fair Value Measurements (Detail

Fair Value Measurements (Details) - Recurring basis - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Total
Fair value
Investment securities - trading	$ 950	$ 989
Total assets measured at fair value on a recurring basis	950	989
Level 1 - Quoted Prices in Active Markets for Identical Assets
Fair value
Investment securities - trading	950	989
Total assets measured at fair value on a recurring basis	950	989
Level 2 - Significant Other Observable Inputs
Fair value
Investment securities - trading	0	0
Total assets measured at fair value on a recurring basis	0	0
Level 3 - Significant Unobservable Inputs
Fair value
Investment securities - trading	0	0
Total assets measured at fair value on a recurring basis	$ 0	$ 0

Revenue Recognition - Narrative

Revenue Recognition - Narrative (Details)	9 Months Ended
	Sep. 30, 2021productCategorysegment
Disaggregation of Revenue [Line Items]
Refund period	90 days
Number of principal categories of products | productCategory	6
Number of business segments | segment	4
Maximum
Disaggregation of Revenue [Line Items]
Contract with customer, contract term	1 year